4-[(4'-(2-甲氧基乙基)苯氧基)甲基]苯硼酸 | 870779-00-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 中文名称: 4-[(4'-(2-甲氧基乙基)苯氧基)甲基]苯硼酸
• 中文别名: 4-[(4’-(2-甲氧基乙基)苯氧基)甲基]苯基硼酸；4-[(4'-(2-甲氧基乙基)苯氧基)甲基]苯基硼酸
• 英文名称: 4-[(4-(2-methoxyethyl)phenoxy)methyl]phenylboronic acid
• 英文别名: (4-((4-(2-Methoxyethyl)phenoxy)methyl)phenyl)boronic acid；[4-[[4-(2-methoxyethyl)phenoxy]methyl]phenyl]boronic acid
• CAS: 870779-00-3
• 化学式: C₁₆H₁₉BO₄
• mdl: MFCD07369748
• 分子量: 286.135
• InChiKey: LZLHTPXZVHZUQB-UHFFFAOYSA-N

物化性质

• 沸点：
  456.7±55.0 °C(Predicted)
• 密度：
  1.17±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.16
• 重原子数：
  21
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  58.9
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2931900090
• 安全说明：
  S26,S36
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

反应信息

• 作为反应物：
  描述：

  4-溴-3-硝基三氟甲苯 、 4-[(4'-(2-甲氧基乙基)苯氧基)甲基]苯硼酸 在 四(三苯基膦)钯 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 以75%的产率得到1-[4-[[4-(2-Methoxyethyl)phenoxy]methyl]phenyl]-2-nitro-4-(trifluoromethyl)benzene
  参考文献：
  名称：

  发现能够抑制mPGES-1的新的有效分子实体

  摘要：

  谷胱甘肽依赖性膜蛋白mPGES-1参与PGE 2的生产，已被公认为开发抗炎和抗癌药物的战略目标。已证明选择性控制炎症刺激诱导的PGE 2水平，既不影响组成性产生的PGE 2，也不影响稳态前列腺素，因此其调节可代表控制PGE 2的更好策略。与使用传统抗炎药相比，这种药物具有严重的副作用。尽管进行了深入的研究以鉴定有效的mPGES-1抑制剂作为药物开发的有吸引力的候选药物，但除LY3023705（最近进入临床试验）外，所公开的分子均无法用于临床，因此发现了新的有效mPGES-迫切需要1种具有类似药物特性的抑制剂。继续我们旨在鉴定能够与该酶相互作用的新化学平台的工作，在此我们描述了通过加工和对接一种有效的mPGES-1调节剂的发现，该调节剂具有基于1-氟-2,4-二硝基联苯的支架。少量可合成的分子集合，围绕两个主要片段构建，在我们的计算机筛选中披露。已合成并测试了得分最高的命中数据，其中五个预测

  DOI：

  10.1016/j.ejmech.2017.10.039

文献信息

• Virtual Fragment Screening Identification of a Quinoline-5,8-dicarboxylic Acid Derivative as a Selective JMJD3 Inhibitor
  作者：Assunta Giordano、Federica del Gaudio、Catrine Johansson、Raffaele Riccio、Udo Oppermann、Simone Di Micco

  DOI：10.1002/cmdc.201800198

  日期：2018.6.20

  The quinoline‐5,8 dicarboxylic acid scaffold has been identified by a fragment‐based approach as new potential lead compound for the development of JMJD3 inhibitors. Among them, 3‐(2,4‐dimethoxypyrimidin‐5‐yl)quinoline‐5,8‐dicarboxylic acid (compound 3) shows low micromolar inhibitory activity against Jumonji domain‐containing protein 3 (JMJD3). The experimental evaluation of inhibitory activity against

  喹啉5,8二羧酸支架已被基于片段的方法鉴定为开发JMJD3抑制剂的新的潜在先导化合物。其中，3-（2,4-二甲氧基嘧啶-5-基）喹啉-5,8-二羧酸（化合物3）对含有Jumonji域的蛋白3（JMJD3）的微摩尔抑制活性较低。对JMJD3的七个相关同工型的抑制活性的实验评估突显了对目标生物学靶标的前所未有的选择性。
• 9<i>H</i>-Purine Scaffold Reveals Induced-Fit Pocket Plasticity of the BRD9 Bromodomain
  作者：Sarah Picaud、Maria Strocchia、Stefania Terracciano、Gianluigi Lauro、Jacqui Mendez、Danette L. Daniels、Raffaele Riccio、Giuseppe Bifulco、Ines Bruno、Panagis Filippakopoulos

  DOI：10.1021/jm501893k

  日期：2015.3.26

  The 2-amine-9H-purine scaffold was identified as a weak bromodomain template and was developed via iterative structure based design into a potent nanomolar ligand for the bromodomain of human BRD9 with small residual micromolar affinity toward the bromodomain of BRD4. Binding of the lead compound 11 to the bromodomain of BRD9 results in an unprecedented rearrangement of residues forming the acetyllysine recognition site, affecting plasticity of the protein in an induced-fit pocket. The compound does not exhibit any cytotoxic effect in HEK293 cells and displaces the BRD9 bromodomain from chromatin in bioluminescence proximity assays without affecting the BRD4/histone complex. The 2-amine-9H-purine scaffold represents a novel template that can be further modified to yield highly potent and selective tool compounds to interrogate the biological role of BRD9 in diverse cellular systems.
• Discovery of new erbB4 inhibitors: Repositioning an orphan chemical library by inverse virtual screening
  作者：Assunta Giordano、Giovanni Forte、Luigia Massimo、Raffaele Riccio、Giuseppe Bifulco、Simone Di Micco

  DOI：10.1016/j.ejmech.2018.04.018

  日期：2018.5

  Inverse Virtual Screening (IVS) is a docking based approach aimed to the evaluation of the virtual ability of a single compound to interact with a library of proteins. For the first time, we applied this methodology to a library of synthetic compounds, which proved to be inactive towards the target they were initially designed for. Trifluoromethyl-benzenesulfonamides 3-21 were repositioned by means of IVS identifying new lead compounds (14-16, 19 and 20) for the inhibition of erbB4 in the low micromolar range. Among these, compound 20 exhibited an interesting value of IC50 on MCF7 cell lines, thus validating IVS in lead repurposing. (C) 2018 Elsevier Masson SAS. All rights reserved.